All News
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Read Article
Spondyloarthritis at ACR Convergence 2020
There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting.
Read Article
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update.
Beautiful organization of targeted therapy in multiple autoimmune diseases.
Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC ( View Tweet)
This convinces me! #TNF inhibitors vs #JAKI
great debate at #ACR20 https://t.co/Xb8KkmDJ8f
KenWarringtonMD MdWarrington ( View Tweet)
New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369
Dr. Antoni Chan synovialjoints ( View Tweet)
Important study helping dissect the JAK-IFN axis I believe - we need to be cautious in attacking this axis as anifrolumab has >2x Zoster of JAKi's- we need to read the tea leaves from IEIs and COVID-19 #ACR20 @JYazdanyMD @Lupusdoc @casanova_lab @cannalab1 https://t.co/scI13jwFZd
Leonard Calabrese LCalabreseDO ( View Tweet)
Lots of JAK safety studies in #ACR20. Abst#0237 pooled 5 RCTs on UPA. Good safety numbers and low VTE rates, but watch out for herpes zoster trend, elevated in UPA (30>15mg) compared to MTX and ADA. @RheumNow
Eric Dein ejdein1 ( View Tweet)
The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow
Eric Dein ejdein1 ( View Tweet)
Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD improved the degree of activity impairment in a clinically relevant manner compared to placebo + csDMARD in pts w/ inadequate response to bDMARD . @RheumNow https://t.co/6M42LUVuht
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
JAKs are no longer new, Winthrop et al presents 8.4 year BARI data in Abst#0202 at #ACR20. VTE risk stable over time, again shows reason to vaccinate patients for zoster before starting. @RheumNow https://t.co/OSIvHl2f7Y
Eric Dein ejdein1 ( View Tweet)
Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest
Robert B Chao, MD doctorRBC ( View Tweet)
#GREATDEBATE Dr. Weinblatt won - but based on the limited # people polled d/t difficulties with website #ACR20 @RheumNow
k dao KDAO2011 ( View Tweet)
The Great Debate results! https://t.co/tJk0yIRqfK
Dr. Rachel Tate uptoTate ( View Tweet)
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs
Peter Nash drpnash ( View Tweet)
Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
Peter Nash drpnash ( View Tweet)
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)
Peter Nash drpnash ( View Tweet)
The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
American College of Rheumatology ACRheum ( View Tweet)
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis https://t.co/I2dzetdgBw
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0
Dr. John Cush RheumNow ( View Tweet)
